MIRA INFORM REPORT

 

 

Report Date :

07.06.2007

 

IDENTIFICATION DETAILS

 

Name :

CAPSUGEL  [THAILAND]  CO.,  LTD.

 

 

Registered Office :

1/82  Moo  5,  Rojana  Industrial  Estate, Rojana  Road,   T.  Kanham,   A.  Uthai,  Ayutthaya  13210

 

 

Country :

Thailand

 

 

Financials (as on) :

30.11.2005

 

 

Date of Incorporation :

1983    

 

 

Com. Reg. No.:

0105526006556

 

 

Legal Form :

Private  Limited  Company

 

 

Line of Business :

Manufacturer  and  distributor  of  gelatin  capsule  and  hard  gelatin  capsules  for  pharmaceutical  and  dietary  supplement  applications.

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Clear

 

 


name

 

CAPSUGEL  [THAILAND]  CO.,  LTD.

 

 

FORMER

 

INTERNATIONAL  CAPSULE  CO., LTD.

 

 

SUMMARY

 

BUSINESS  ADDRESS                          :           1/82  MOO  5,  ROJANA  INDUSTRIAL  ESTATE,

                                                                        ROJANA  ROAD,   T.  KANHAM,   A.  UTHAI, 

                                                                        AYUTTHAYA  13210,  THAILAND

TELEPHONE                                         :           [66]   35  334-000,  35  334-050              

FAX                                                      :           [66]   35  334-001,  35  227-088              

E-MAIL  ADDRESS                                :           kriengsak.piyathanavong@pfizer.com     

REGISTRATION  ADDRESS                  :           SAME  AS  BUSINESS  ADDRESS

             

ESTABLISHED                                     :           1983    

REGISTRATION  NO.                           :           0105526006556  [Former : 655/2526]      

CAPITAL REGISTERED                         :           BHT.   170,000,000

CAPITAL PAID-UP                                :           BHT.   170,000,000

FISCAL YEAR CLOSING DATE              :           NOVEMBER  30  

LEGAL  STATUS                                  :           PRIVATE  LIMITED  COMPANY

EXECUTIVE                                          :           MR.  WANCHAI  SANTIMANOCHAI,  THAI

                                                                        MANAGING  DIRECTOR

             

NO.  OF  STAFF                                   :           200

LINES  OF  BUSINESS                          :           CAPSULE  PRODUCTS

                                                                        MANUFACTURER  &  DISTRIBUTOR     

 

 

CORPORATE  PROFILE

 

OPERATING  TREND                            :           STABLE                       

PRESENT  SITUATION                          :           OPERATING  NORMALLY                     

REPUTATION                                       :           GOOD  WITH  NORMAL  BUSINESS  ENGAGEMENT    

MANAGEMENT  STANDARD                 :           MANAGEMENT  WITH   AVERAGE  PERFORMANCE

 

 

 


 

HISTORY

 

The   subject    was  established   on  February  17,  1983  as   a   private   limited   company under  the  registered  name  International  Capsule  Co., Ltd.,  by  Thai  and  Dutch  Groups.  On  February  12,  2002, the subject  was  changed  its  name  to  be  CAPSUGEL  [THAILAND]  CO., LTD.    It  currently  employs  approximately  200  staff.

 

The  subject  is  a  joint  venture  between  “O.C.T.  [Thailand]  Ltd.”  and  “Pfizer  B.V.”, with  51%  and  49%  of  investment  respectively.  It  is  an  affiliate  of  Capsugel,  the  world’s  leading  two-piece  hard  gelatin  capsule  producer  and  a  division  of  Pfizer  Inc.

 

On  February  1,  1999,  the  subject  received  the  International  Standard  ISO  9002  certification  to  manufacture  of  hard  gelatin  capsules  by  RWTUV,  and  ISO  14001  certificate  for  environmental  system  by  RWTUV  on  March  7,  2003.

 

On  October  25,  2000,  the  subject  was  invested  about  500  million  baht  and  270  million  baht  to  produce  5,250  million  of  gelatin  capsules  and  5,250  million  of  hard  gelatin  capsules  per  year  respectively  with  BOI  promoted. 

 

The subject adopts the Acceptable Quality Level (AQL) standard, in addition to the ISO 9001:2000 quality management system, to create quality consciousness.

 

The  subject’s  registered  address  is  1/82  Moo 5,  Rojana  Rd.,  T. Kamham,  A. Uthai,  Ayutthya  13210,  and  this  is  the  subject’s  current  operation  address.

 

 

THE  BOARD  OF  DIRECTORS

 

            Name                                                   Nationality                   Age

 

Mr.  Kriengsak  Piyatanawong                                Thai                          51

Mr. Charles  R.  Donjout                                      French                        63

Ms.  Vilaiporn    Laochuwongse                               Thai                          54

Mr.  Wanchai  Santimanochai                                Thai                          51

Mr.  Guido  Edouard  Driesen                                Belgian                       51

 

 

AUTHORIZED  PERSON

 

Two  of  the  above  directors  can  jointly  sign  on  behalf  of  the  subject  with  company’s  affixed.

 

 

MANAGEMENT

 

Mr.  Wanchai  Santimanochai  is  the  Managing  Director.

He  is  Thai  nationality  with  the  age  of  51  years  old.

 

Ms.  Vilaiporn    Laochuwongse  is  the  Finance  &  Account  Manager.

She  is  Thai  nationality  with  the  age  of  54  years  old.

 

Mr.  Kriengsak  Piyatanawong  is  the  Marketing  &  Sales  Director.

He  is  Thai  nationality  with  the  age  of  51  years  old.

 

Ms.  Lu  Jin  Hua  is  the  Factory  Manager.

She  is  Chinese  nationality.

 

Ms.  Chotika  Pudpad  is  the  Human  Resources  Manager.

She  is  Thai  nationality.

 

 

BUSINESS  OPERATIONS

 

The subject’s  activities  are  manufacturer  and  distributor  of  gelatin  capsule  and  hard  gelatin  capsules  for  pharmaceutical  and  dietary  supplement  applications.  Its  products    include  Coni-snap  capsules,  Vcap  capsules,  Licaps  capsules,  PCcaps  capsules,  Press-fit  capsules,  DBcaps  capsules  &  NP  caps  capsules,  as  well  as  dietary  supplement  applications.

 

 

IMPORT  [COUNTRIES]

 

Most of  its  raw  materials  for  processing  such  as  gelatin  are  imported  from  Japan  and  the  others are from Germany,  United States of America,  Netherlands,  France  and  United Kingdom. 

 

 

MAJOR  SUPPLIER

 

Pfizer  Inc.                     :  United  States  of  America

 

 

SALES  [LOCAL]

 

70%  of  its  products  is  sold  locally  to  manufacturers,  wholesalers  and  end-users.

 

 

EXPORT  [COUNTRY]

 

70%  of  its  products  is  exported  to  Malaysia,  Australia,  New  Zealand,  Vietnam,  India,  Singapore  and  Pakistan.

 

 

MAJOR  CUSTOMERS

 

Pharmaceutical  Organizations  and  manufactures

 

 

LITIGATION

 

Bankruptcy  and  Receivership

 

There  are  no  litigation  on  bankruptcy  and  receivership  cases  filed  against  the  subject  found  at  Legal  Execution  Department  for  the  past  five  years.

 

Others

 

There  are  no  legal  suits  filed  against   the  subject for  the  past  two  years.

 

 

CREDIT  

 

Sales  are  by  cash  or  on  the  credits  term  of  30-60 days.

Local  bills  are  paid  by  cash  or  on  the  credits  term  of  30-60-90  days.

Imports  are  by  L/C  at  sight  or  T/T  on  negotiated  term.

Exports  are  against  L/C  at  sight  or  T/T  on  negotiated  term. 

 

 

BANKING

 

Bangkok   Bank  Public  Co., Ltd.       

  [Rojana  Branch : Rojana Rd.,  Uthai,  Ayutthaya  13210]

 

Citibank,  NA                                       

  [Bangkok  Branch : 82  North  Sathorn  Rd.,  Bangrak,  Bangkok  10500]

 

 

EMPLOYMENT

 

The  subject  employs   approximately  200  staff.  [office  staff  and  factory  workers]

 

 

LOCATION   DETAILS

 

The  premise  is   rented  for  administrative  office  and  factory  at  the  heading  address.  Premise  is  located  in  an  industrial  area.

 

The  subject  was  relocated  its  office  from 15th  Floor,  Sino-Thai  Tower,  32/39  Sukhumvit  21  Rd.  to  the  present  address  in  August  2001.

 

 

COMMENT

 

The subject is  a production facility of Capsugel, a leading global manufacturer of capsules for pharmaceutical and dietary supplement applications. With its headquarters in New Jersey, U.S.A.  Capsugel has nine production plants in South Carolina (U.S.A.), Mexico, Brazil, Belgium, France,  Indonesia,  Japan,  China  and  Thailand.

 

Capsugel (Thailand) Co., Ltd. adheres to strict Good Manufacturing Practice (GMP) standards, in accordance with its parent company’s strict quality policy, and utilizes state-of-the-art technology, equipment and production techniques that have been proven effective around the globe.

 

The subject has become the group’s export center for the Asian market, as well as Australia and New Zealand.

 

Local  demand  for  capsule  products  consumption  has  significantly  increased  due  to  pharmaceutical  and  health  food  supplement  industry  are  growing   in  high demand.

 

Local  pharmaceutical  and  food  supplement  industries  has  shown  strong  growth  both  local  and  international  markets.  The industry  outlook  is  soaring.

 

The  subject  has  maintained  its  leading  role  in the  industry  and  expanding  steadily.

 

 

FINANCIAL  INFORMATION

 

The  capital   was  registered  at  Bht.  1,000,000  divided  into  10,000  shares  of  Bht.  100  each.

 

The  capital  was  increased  later  as  followings  :

 

            Bht.   30,000,000  on  April    3,  1986

            Bht.   70,000,000  on  April  12,  1988

            Bht.   90,000,000  on  June  17,  1998

            Bht. 170,000,000  on  June  17,  2004

 

The  latest  registered  capital  was  increased  to  Bht.  170,000,000  divided  into  1,700,000  shares  of   Bht.  100  each  with  fully  paid.

 

 

THE  SHAREHOLDERS  LISTED  WERE  :  [as  at  March  31,  2006]

 

              NAME

HOLDING

%

 

 

 

Pfizer   B.V.

Nationality: Dutch

Address    : Netherlands

1,240,999

49.00

O.C.T.  [Thailand]  Ltd.

Nationality: Thai

Address    : 1/82  Moo 5,  Rojana Rd.,  T. Kanham,

                  A. Uthai,  Ayutthaya  13210

  458,996

51.00

Warner - Lambert  [Thai]  Ltd.

Nationality: Thai

Address    :  323  Silom Rd.,  Silom,  Bangrak, Bangkok  10500

           1

-

Renroll  LLC

Nationality: American

Address    :  201  Tabor  Rd.,  Morris  Plains,  New Jersey, U.S.A.

           1

-

Solinor  LLC

Nationality: American

Address    : 201  Tabor  Rd.,  Morris  Plains,  New Jersey, U.S.A.

           1

-

International  Affiliated  Corporation  LLC

Nationality:  American

Address    :   201  Tabor  Rd.,  Morris  Plains,  New Jersey, U.S.A.

           1

-

Tebor  Corporation

Nationality: American

Address    :  201  Tabor  Rd.,  Morris  Plains,  New Jersey, U.S.A.

           1

-

 

 

Total  Shareholders 

 

7

 

NAME  OF  AUDITOR  &  CERTIFIED  PUBLIC

ACCOUNTANT  NO.

 

Mr.  Vichien  Thamtrakul  No.  3183

 


 

BALANCE SHEET [BAHT]

 

 

The  latest  financial  figures  published  for  November  30,  2005 & 2004  were:

          

ASSETS

                                                                                                 

Current Assets

2005

2004

 

 

 

Cash   in   hand  &  at  Bank             

159,318

2,300,504

Trade  Accts.  &  Notes  Receivable  

248,629,420

239,332,474

Inventories                                         [note 1]   

68,725,239

71,608,724

Account  Receivable – Related  Company

4,331,288

7,255,955

Refundable  Value  Added  Tax

27,348,285

29,868,570

Other  Current  Assets                  

2,815,505

7,654,040

 

 

 

Total  Current  Assets                

352,009,055

358,020,267

 

Fixed Assets                                     [note 2]      

 

836,144,107

 

851,336,067

Deposit                          

1,147,936

2,807,936

 

Total  Assets                 

 

1,189,301,098

 

1,212,164,270


 

LIABILITIES & SHAREHOLDERS' EQUITY [BAHT]

 

 

Current Liabilities

2005

2004

 

 

 

Bank  Overdraft

-

2,223,430

Trade  Accounts  Payable

92,387,045

60,826,957

Account  Payable  -  Related  Company

193,050

1,375,041

Short-term  Loan  from  Related  Company

440,000,000

646,242,144

Accrued  Expenses

33,611,503

40,197,992

Accrued Income  Tax

4,770,982

77,049

Revenue  Expenses

7,406,457

2,494,427

Other  Current  Liabilities             

27,974,299

14,866,837

 

 

 

Total  Current  Liabilities

606,343,336

768,226,828

 

 

 

Shareholders' Equity

 

 

 

 Share  capital : Baht  100  value 

  authorized,  issued  and  fully 

  paid  share  capital  1,700,000  shares

 

 

 

170,000,000

 

 

 

170,000,000

 

 

 

Capital  Paid                      

170,000,000

170,000,000

Retained  Earning

  Appropriated  for  Statutory  Reserve      

 

17,000,000

 

8,353,575

  Unappropriated  [Deficit]

395,957,762

265,583,867

 

Total Shareholders' Equity

 

582,957,762

 

443,937,442

 

Total Liabilities  & Shareholders'  Equity

 

1,189,301,098

 

1,212,164,270

 


 

PROFIT  &  LOSS  ACCOUNT

 

 

Revenue

2005

2004

 

 

 

Sales                                         

906,813,690

819,645,777

Other  Income

9,875,262

3,446,502

 

Total  Revenues           

 

916,688,952

 

823,092,279

 

Expenses

 

 

 

 

 

Cost   of   Goods   Sold                           

537,198,017

503,038,073

Selling  &  Administrative  Expenses

132,091,065

134,317,252

 

 

 

Total  Expenses

669,289,082

637,355,325

 

 

 

Profit / [Loss]  before  Interest  Expenses  &

  Income  Tax

 

247,399,870

 

185,736,954

Interest  Expenses          

[9,250,486]

[219,958]

Income  Tax

[9,129,064]

[112,262]

 

Net  Profit / [Loss]

 

229,020,320

 

185,404,734

 


 

FINANCIAL  NOTE

 

NOTE  1  Inventories

 

 

2005

2004

 

 

 

Finished  Goods

29,482,437

42,544,862

Raw  Material

29,375,319

22,807,902

Works  in  Progress

-

3,486,750

Material  Supplies

-

1,959,791

Good

3,828,001

15,237,884

Goods  in  Transit

16,654,358

-

  Total

79,340,115

86,037,189

  Less:  Allowance  for  Stock  Obsolescence

[10,614,876]

[14,428,465]

 

   Total      

 

68,725,239

 

71,608,724

 

NOTE  2  Fixed  Assets

 

 

2005

2004

 

 

 

Land

38,247,010

39,421,335

Building & Construction

156,432,956

156,432,956

Machine & Equipment

1,131,066,533

1,041,461,797

Office Automation & Furniture

27,122,213

24,658,501

Vehicle

7,520,098

2,119,713

Assets  under  Installation

6,225,198

7,378,707

  Total

1,366,614,008

1,271,473,009

  Less: Depreciation

[530,469,901]

[420,136,942]

 

  Total

 

836,144,107

 

851,336,067

 


 

FINANCIAL  ANALYSIS

 

Annual  Growth  &  Profitability

 

 

Annual  Growth

 

2005

 

2004

 

Net  Sales

 

10.63

 

 

 

Operating  Profit

 

20.40

 

 

 

Net  Profit

 

23.52

 

 

 

Fixed  Assets

 

[1.78]

 

 

 

Total  Assets

 

[1.89]

 

 

 

Profitability

 

 

 

 

 

Cost  of  Good  Sold

 

59.24

 

61.37

 

Operating  Profit  Margin

 

27.28

 

22.66

 

S  &  A  Expenses

 

14.57

 

16.39

 

Interest Paid

 

1.02

 

0.03

 

Other  Revenues

 

1.09

 

0.42

 

Net  Profit  Margin

 

25.26

 

22.62

 

Earning  Per  Shares

 

134.72

 

109.06

 

No. of  Shares

 

1,700,000

 

1,700,000

 

Net  Sales  was  increased  by  10.63%,  Operating  Profit  was  increased  by  20.40%,  Net  Profit  was  increased  by  23.52%,  Fixed  Assets  was  decreased  by  1.78%,  Total  Assets  was  decreased  by  1.89%.


 

 

Compare  each  cost  with  sales, Cost  of  Good  Sold  was  decreased  from  61.37%  to  59.24%,  Operating  Profit  Margin  was  increased  from  22.66%  to  27.28%,  S  &  A  Expenses  was  decreased  from  16.39%  to  14.57%,  Interest Paid  was  increased  from  0.03%  to  1.02%,  Other  Revenues  was  increased  from  0.42%  to  1.09%,  Net  Profit  Margin  was  increased  from  22.62%  to  25.26%. 

 

Earning  Per  Shares  was  increased  from  109.06  baht  per  share  to  134.72  baht  per  share.

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

Liquidity

 

 

Liquidity

 

2005

 

2004

 

Current  Ratio

 

0.58

 

0.47

 

Quick-Assets  Ratio

 

0.41

 

0.31

 

Current  Ratio  was  increased  from  0.47  to  0.58,  show  Current  Assets  can  not  cover  Current  Liabilities,  Liquidity  Ratio  of  the  company  was  not  good,  Quick-Assets  Ratio  was  increased  from  0.31  to  0.41,  capacity  to  pay  Short  Term  Loan  was  not  good  too,  because  Current  Assets  without  Inventory  can  not  cover  Current  Liabilities.

 

 

 

 

 

 

 

 

 

 

 

 

 


 

Leverage

 

 

Leverage

 

2005

 

2004

 

D/E  Ratio

 

1.04

 

1.73

 

Times  Interest  Earned

 

26.74

 

844.42

 

D/E  Ratio  was  decreased  from  1.73  to  1.04,  show  the  company  had  fund  from  Loan  more  than  fund  from  Equity,  investment  risked  of  the  company  is  medium,  Times  Interest  Earned  was  decreased  from  844.42  to  26.74,  capacity  to  pay  interest  paid  was  good.

 

 

 

 

 

 

 

 

 

 

 

 

 


Efficiency

 

 

Efficiency

 

2005

 

2004

 

Fixed  Assets  Turnover

 

1.08

 

0.96

 

Total  Assets  Turnover

 

0.76

 

0.68

 

Return  on  Assets

 

19.26

 

15.30

 

Return  on  Equity

 

39.29

 

41.76

 

Day's  Payable

 

36.68

 

26.72

 

Day’s  Inventories

 

27.28

 

31.45

 

Day’s  Receivables

 

98.70

 

105.12

 

Fixed  Assets  Turnover  was  increased  from  0.96  times  to  1.08  times,  Total  Assets  Turnover  was  increased  from  0.68  times  to  0.76  times,  show  the  company  could  use  Assets  so  efficiently,  Return  on  Assets  was  increased  from  15.30  to  19.26,  Return  on  Equity  was  decreased  from  41.76  to  39.29,  capacity  to  use  Assets  to  make  profit  was  good. 

 

Day's  Payable  was  increased  from  27  days  to  37  days,  while  Day’s  Inventories  was  decreased  from  32  days  to  28  days,  and  Day’s  Receivables  was  decreased  from  106  days  to  99  days.

 

 


 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Unfavourable & favourable factors carry similar weight in credit consideration. Capability to overcome financial difficulties seems comparatively below average/normal.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

NR

In view of the lack of information, we have no basis upon which to recommend credit dealings

No Rating

 

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions